Answer
Granulocyte macrophage-colony stimulating factor (GM-CSF) should be avoided during cytokine release syndrome (CRS) associated with Tecvayli (teclistamab) because it has the potential to worsen CRS symptoms.
Sources for this answer
- TECVAYLI 90mg/ml solution for injectionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 9Document updated
Sources checked